Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.
[More]
A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer.
[More]
For the first time, scientists at the Toronto General Research Institute showed that targeting glucagon action in the brain may be a new frontier for regulating diabetes.
[More]
A medication’s optimal results are achieved with specific dose levels and times of administration. In order for patients to achieve the maximum benefit from a medication, they have to adhere to the prescribed dose and time of use.
[More]
There are significant cost and risk factors associated with two procedures commonly used to diagnose or treat gastrointestinal problems, according to research presented at Digestive Disease Week.
[More]
In the wake of actress Angelina Jolie's public announcement that she recently underwent a preventive double mastectomy, Loma Linda University Medical Center urges women with a family history of cancer to have proper counseling and testing, if indicated, to see if they are at similar risk.
[More]
Singapore's Agency for Science, Technology and Research and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle technology.
[More]
Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, a Mayo Clinic study has found.
[More]
Researchers at Cedars-Sinai have launched a new clinical trial to investigate the effects of a cancer-fighting drug therapy that has shown favorable outcomes in patients with advanced metastatic prostate cancer.
[More]
Most cancer patients would like to talk about the cost of their care with their doctors, but often don't because they fear the discussion could compromise the quality of their treatment, researchers at Duke Cancer Institute report.
[More]
Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital in the UK.
[More]
Transgenomic, Inc. today announced the global, commercial availability of CRC RAScan, a new mutation detection test to screen patients with metastatic colorectal cancer for RAS mutations (KRAS and NRAS).
[More]
DiagnoCure Inc., today announced that results from a large validation study of the PrevistageTM GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology Annual Meeting, taking place in Chicago, Illinois from May 31 to June 4, 2013.
[More]
Researchers from University Hospitals Case Medical Center's Seidman Cancer Center will present findings from two studies evaluating new technologies designed to address common barriers to patient enrollment in clinical trials.
[More]
Third-year residents in the Department of Family and Community Medicine at Thomas Jefferson University Hospital have organized a symposium examining racial and ethnic health disparities, with a focus on cancer care. The program will feature a keynote speech from Otis Brawley, MD, Chief Medical Officer of the American Cancer Society.
[More]
The majority of cancer doctors, patients, and members of the general public support cutting health care costs by refusing to pay for drugs that don't improve survival or quality of life, according to results of a new study that will be presented by researchers from the Perelman School of Medicine at the University of Pennsylvania during the annual meeting of the American Society of Clinical Oncology in Chicago in early June (Abstract #6518).
[More]
Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).
[More]
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.
[More]
The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.
[More]
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
[More]